Connor, Clark & Lunn Investment Management Ltd. Ultragenyx Pharmaceutical Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $21.1 Billion
  • Q1 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 44,901 shares of RARE stock, worth $1.67 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
44,901
Previous 27,016 66.2%
Holding current value
$1.67 Million
Previous $1.14 Million 43.05%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$36.21 - $45.78 $647,615 - $818,775
17,885 Added 66.2%
44,901 $1.63 Million
Q4 2024

Feb 10, 2025
SELL
$42.07 - $57.72 $2.03 Million - $2.78 Million
-48,249 Reduced 64.11%
27,016 $1.14 Million
Q3 2024

Nov 08, 2024
SELL
$40.21 - $59.36 $3.52 Million - $5.2 Million
-87,626 Reduced 53.79%
75,265 $4.18 Million
Q2 2024

Aug 09, 2024
BUY
$37.42 - $51.61 $275,635 - $380,159
7,366 Added 4.74%
162,891 $6.69 Million
Q1 2024

May 09, 2024
BUY
$43.02 - $53.69 $2.97 Million - $3.71 Million
69,068 Added 79.89%
155,525 $7.26 Million
Q4 2023

Feb 09, 2024
SELL
$31.73 - $49.19 $3.04 Million - $4.71 Million
-95,778 Reduced 52.56%
86,457 $4.13 Million
Q3 2023

Nov 13, 2023
SELL
$34.92 - $46.66 $830,956 - $1.11 Million
-23,796 Reduced 11.55%
182,235 $6.5 Million
Q2 2023

Aug 10, 2023
SELL
$37.35 - $52.15 $68,238 - $95,278
-1,827 Reduced 0.88%
206,031 $9.5 Million
Q1 2023

May 09, 2023
SELL
$36.99 - $48.71 $826,208 - $1.09 Million
-22,336 Reduced 9.7%
207,858 $8.34 Million
Q4 2022

Feb 10, 2023
BUY
$33.72 - $46.33 $1.41 Million - $1.94 Million
41,773 Added 22.17%
230,194 $10.7 Million
Q3 2022

Nov 10, 2022
BUY
$39.96 - $66.14 $6.23 Million - $10.3 Million
155,840 Added 478.32%
188,421 $7.8 Million
Q2 2022

Aug 05, 2022
BUY
$45.8 - $85.4 $1.49 Million - $2.78 Million
32,581 New
32,581 $1.94 Million
Q3 2021

Nov 12, 2021
SELL
$77.92 - $102.4 $183,657 - $241,356
-2,357 Closed
0 $0
Q2 2021

Aug 12, 2021
SELL
$92.19 - $115.71 $1.21 Million - $1.52 Million
-13,109 Reduced 84.76%
2,357 $225,000
Q1 2021

May 13, 2021
BUY
$106.9 - $167.73 $1.37 Million - $2.15 Million
12,840 Added 488.96%
15,466 $1.76 Million
Q4 2020

Feb 16, 2021
BUY
$84.4 - $177.39 $221,634 - $465,826
2,626 New
2,626 $364,000

Others Institutions Holding RARE

# of Institutions
336
Shares Held
88.9M
Call Options Held
1.08M
Put Options Held
1.04M
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.6B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email